Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
Hofmann WP, Buggisch P, Schubert L, Dikopoulos N, Schwenzer J, Muche M, Felten G, Heyne R, Ingiliz P, Schmidt A, Stein K, Wedemeyer H, Berg T, Wiegand J, Lammert F, Zeuzem S, Schattenberg JM. Hofmann WP, et al. Among authors: buggisch p. JHEP Rep. 2020 Aug 4;2(6):100168. doi: 10.1016/j.jhepr.2020.100168. eCollection 2020 Dec. JHEP Rep. 2020. PMID: 32964201 Free PMC article.
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. Berg T, et al. Among authors: buggisch p. Gastroenterology. 2006 Apr;130(4):1086-97. doi: 10.1053/j.gastro.2006.02.015. Gastroenterology. 2006. PMID: 16618403 Clinical Trial.
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.
Kronenberger B, Berg T, Herrmann E, Hinrichsen H, Gerlach T, Buggisch P, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S. Kronenberger B, et al. Among authors: buggisch p. Eur J Gastroenterol Hepatol. 2007 Aug;19(8):639-46. doi: 10.1097/MEG.0b013e3281ac20ca. Eur J Gastroenterol Hepatol. 2007. PMID: 17625432 Clinical Trial.
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection.
Halangk J, Sarrazin C, Neumann K, Puhl G, Mueller T, Teuber G, Klinker H, Hinrichsen H, Buggisch P, Landt O, Weich V, Bergk A, Wiedenmann B, Neuhaus P, Berg T, Witt H. Halangk J, et al. Among authors: buggisch p. J Hepatol. 2008 Sep;49(3):339-45. doi: 10.1016/j.jhep.2008.05.021. Epub 2008 Jun 23. J Hepatol. 2008. PMID: 18644651
The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection.
Deterding K, Wiegand J, Grüner N, Hahn A, Jäckel E, Jung MC, Buggisch P, Galle P, Berg T, Hinrichsen H, Potthoff A, Zeuzem S, Cornberg M, Manns M, Wedemeyer H. Deterding K, et al. Among authors: buggisch p. Z Gastroenterol. 2009 Jun;47(6):531-40. doi: 10.1055/s-0028-1109149. Epub 2009 Jun 16. Z Gastroenterol. 2009. PMID: 19533544
147 results